Masimo is a global medical technology company that develops and manufactures innovative noninvasive patient monitoring technologies, including medical devices and a wide array of sensors.

 
  • We Just Raised the Standard, Again
  • SpO2 Accuracy Is Now Better Than Ever With RD SET™
 
  • Oxygen Reserve Index (ORi™)
  • A noninvasive and continuous parameter that provides insight into a patient’s oxygen reserve
 
  • rainbow® Pulse CO-Oximetry
  • The Masimo rainbow SET™ platform has the unique ability to measure dyshemoglobins and total hemoglobin concentration.
 
 
  • CCHD Screening
  • Reliable, Accurate Screening for Critical Congenital Heart Disease (CCHD) with Masimo SET®

News & Media

 
  • August 7, 2019
  • Neuchatel, Switzerland
  • Masimo (NASDAQ: MASI) announced today that in a study published in the Journal of Clinical Monitoring and Computing, researchers investigated the effects of implementing a hospital-wide fluid and blood administration protocol using two Masimo measure […]
  • August 5, 2019
  • Neuchatel, Switzerland
  • Masimo (NASDAQ: MASI) announced today the CE marking of SpHb®, noninvasive and continuous hemoglobin monitoring, for neonatal and infant patients (< 3 kg). With this clearance, the benefits of SpHb are available for patients of all ages in CE mark co […]
  • July 22, 2019
  • Neuchatel, Switzerland
  • Masimo (NASDAQ: MASI) announced today that in a study recently published in Anesthesia & Analgesia, researchers evaluated the ability of noninvasive and continuous hemoglobin monitoring with Masimo SpHb® to detect the development of acute hemodilutio […]

Discover More at Masimo

 
  • March 2, 2018
  • Masimo Personal Health
  • MightySat is for people who want to improve their health, wellness, or fitness by providing key measurements that are more accurate & not available on other health and wellness devices. […]
  • February 23, 2018
  • Patient Safety Movement
  • The Patient Safety Movement Foundation believes reaching ZERO preventable deaths in hospitals by 2020 (0X2020™) is not only the right goal, but an attainable one with the […]
  • June 4, 2018
  • 2017 Masimo Annual Report
  • 2017 Masimo Annual Report - Automating Care. Reflecting on the Past and Defining the Future. […]

Next Generation SedLine is not licensed for sale in Canada.

For professional use. See instructions for use for full prescribing information, including indications, contraindications, warnings, and precautions.

Improving Patient Outcomes and Reducing the Cost of Care®

© 2019 Masimo. All Rights Reserved.